HNF4A immunohistochemistry facilitates distinction between primary and metastatic breast and gastric carcinoma

Autor: Peter Bult, J.H.J.M. van Krieken, M.J.L. Ligtenberg, R S van der Post, Ingrid P. Vogelaar, Nicoline Hoogerbrugge
Rok vydání: 2014
Předmět:
endocrine system
Pathology
medicine.medical_specialty
Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2]
Estrogen receptor
Breast Neoplasms
Adenocarcinoma
Sensitivity and Specificity
Pathology and Forensic Medicine
Metastasis
Breast cancer
Stomach Neoplasms
Progesterone receptor
Tumours of the digestive tract Radboud Institute for Molecular Life Sciences [Radboudumc 14]
Biomarkers
Tumor
Humans
Medicine
skin and connective tissue diseases
Molecular Biology
Aged
Women's cancers Radboud Institute for Molecular Life Sciences [Radboudumc 17]
business.industry
Stomach
digestive
oral
and skin physiology
Cancer
Cell Biology
General Medicine
Middle Aged
medicine.disease
Immunohistochemistry
digestive system diseases
medicine.anatomical_structure
Hepatocyte Nuclear Factor 4
Tissue Array Analysis
Female
business
Breast carcinoma
Zdroj: Virchows Archiv, 464, 673-9
Virchows Archiv, 464, 6, pp. 673-9
ISSN: 1432-2307
0945-6317
DOI: 10.1007/s00428-014-1574-x
Popis: Contains fulltext : 138138.pdf (Publisher’s version ) (Closed access) The distinction between primary gastric adenocarcinoma and gastric metastatic breast carcinoma can be difficult. Expression of hepatocyte nuclear factor 4A (HNF4A) has been described as being specific to distinguish between neoplastic gastric and breast epithelial cells. The aim of this study was to validate the use of HNF4A with immunohistochemistry in discriminating gastric from breast carcinomas. Immunohistochemical expressions of HNF4A, estrogen receptor (ER), progesterone receptor (PR), and BRST-2 were determined in primary sporadic gastric adenocarcinomas (n = 107) and breast carcinomas (n = 105). The same markers and clinicopathological features were studied in 1 patient with breast metastasis of gastric cancer, 6 patients with gastric metastases of breast cancer, and 13 patients with both primary gastric and breast carcinomas. HNF4A expression was seen in 106 of 107 primary gastric adenocarcinomas and was absent in all 105 primary breast carcinomas (sensitivity 99 %, specificity 100 %). ER, PR, and BRST-2 were 100 % specific for breast carcinomas with sensitivities of 77, 58, and 38 %, respectively. The metastasis of gastric carcinoma to the breast showed strong expression of HNF4A. None of the metastases of breast carcinomas to the stomach showed expression of HNF4A. Tissues of patients with two primary carcinomas showed strong expression of HNF4A in all gastric carcinomas and no expression in breast carcinomas. Our results indicate that HNF4A is a very good marker to discriminate between primary and metastatic gastric and breast carcinomas.
Databáze: OpenAIRE
Externí odkaz: